Press release
Diabetic Macular Edema Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approval, NDA Approval, Mechanism of Action, Route of Administration, and Companies by DelveInsight
(Albany, United States) "Diabetic Macular Edema Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Macular Edema Market.As per DelveInsight's assessment, globally, Diabetic Macular Edema pipeline constitutes key companies continuously working towards developing Diabetic Macular Edema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Macular Edema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample report @ https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Diabetic Macular Edema Pipeline Report:
• Diabetic Macular Edema Companies across the globe are diligently working toward developing novel Diabetic Macular Edema treatment therapies with a considerable amount of success over the years.
• Diabetic Macular Edema companies working in the treatment market are Eluminex BioSciences, Ocugen, Innovent biologics, Curacle, GlaxoSmithKline, Exonate Limited, Ocuphire Pharma, Unity Biotechnology, Allgenesis Biotherapeutics Inc., Mylan, Kodiak Sciences, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Oxurion, Novartis, YD Life Science, Allegro, Opthalmics/Bausch Health, Clearside Biomedical, KalVista Pharmaceuticals, and others, are developing therapies for the Diabetic Macular Edema treatment
• Emerging Diabetic Macular Edema therapies in the different phases of clinical trials are- EB-102, OCU200, IBI324, CU06-1004, GSK-2798745, EXN407, APX3330, UBX1325, AG-73305, MYL-1701P, KSI-301, BEOVU (RTH258; brolucizumab), VABYSMO (faricimab), KSI-301, ADVM-022, GB-102, THR-149, LKA651, YD-312, Luminate (ALG-1001, Risuteganib), Xipere (CLS-TA), KVD001, and others are expected to have a significant impact on the Diabetic Macular Edema market in the coming years.
• In January 2025, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene and cell therapies, biologics, and vaccines, has announced that the first patient has been dosed in its Phase 1 OCU200 clinical trial for the treatment of diabetic macular edema (DME).
• In October 2024, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced positive one-year topline results from the Phase IV ELEVATUM study, an open-label, single-arm trial assessing Vabysmo® (faricimab-svoa) for diabetic macular edema (DME) in racial and ethnic groups often underrepresented in clinical research.
• In October 2024, Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company dedicated to advancing eye care and preserving vision, has announced an update on the DIAMOND Phase 3 program for OCS-01, a high-concentration dexamethasone eye drop using OPTIREACH® technology for diabetic macular edema (DME). The update will be presented by Dr. David Eichenbaum at Innovate Retina. Additionally, Dr. Riad Sherif, Oculis' CEO, will speak at Eyecelerator 2024, ahead of the American Academy of Ophthalmology Annual Meeting, where Oculis will be exhibiting (booth 5452).
• In September 2024, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, along with its subsidiary EyeBio, has announced the launch of the Phase 2b/3 BRUNELLO trial to evaluate RestoretTM (MK-3000, formerly EYE103) for the treatment of diabetic macular edema (DME).
Diabetic Macular Edema Overview
Diabetic Macular Edema (DME) is a severe eye condition that affects individuals with diabetes and is a leading cause of vision impairment among diabetic patients. Diabetic Macular Edema occurs when prolonged high blood sugar levels damage the blood vessels in the retina, leading to fluid accumulation in the macula - the central part of the retina responsible for sharp vision. Diabetic Macular Edema can develop at any stage of diabetic retinopathy and may affect one or both eyes. Diabetic Macular Edema symptoms include blurred or wavy vision, color perception changes, and difficulty reading or recognizing faces.
Diabetic Macular Edema diagnosis typically involves comprehensive eye exams, including optical coherence tomography (OCT) and fluorescein angiography. Diabetic Macular Edema treatment options include anti-VEGF injections, corticosteroids, laser therapy, and tight control of blood sugar, blood pressure, and cholesterol levels. Diabetic Macular Edema prognosis varies depending on how early the condition is detected and treated.
Diabetic Macular Edema awareness is crucial for early intervention and preventing permanent vision loss. Diabetic Macular Edema research continues to evolve, with ongoing clinical trials exploring more effective and long-lasting therapies. Diabetic Macular Edema management requires a multidisciplinary approach involving ophthalmologists, endocrinologists, and primary care physicians to optimize patient outcomes.
Get a Free Sample PDF Report to know more about Diabetic Macular Edema Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Diabetic Macular Edema Drugs Under Different Phases of Clinical Development Include:
• EB-102: Eluminex BioSciences
• OCU200: Ocugen
• IBI324: Innovent biologics
• CU06-1004: Curacle
• GSK-2798745: GlaxoSmithKline
• EXN407: Exonate Limited
• APX3330: Ocuphire Pharma
• UBX1325: Unity Biotechnology
• AG-73305: Allgenesis Biotherapeutics Inc.
• MYL-1701P: Mylan
• KSI-301: Kodiak Sciences
• BEOVU (RTH258; brolucizumab): Novartis
• VABYSMO (faricimab): Roche
• KSI-301: Kodiak Sciences
• ADVM-022: Adverum Biotechnologies
• GB-102: Graybug Vision
• THR-149: Oxurion
• LKA651: Novartis
• YD-312: YD Life Science
• Luminate (ALG-1001, Risuteganib): Allegro Opthalmics/Bausch Health
• Xipere (CLS-TA): Clearside Biomedical
• KVD001: KalVista Pharmaceuticals
Diabetic Macular Edema Pipeline Therapeutics Assessment
• Diabetic Macular Edema Assessment by Product Type
• Diabetic Macular Edema By Stage and Product Type
• Diabetic Macular Edema Assessment by Route of Administration
• Diabetic Macular Edema By Stage and Route of Administration
• Diabetic Macular Edema Assessment by Molecule Type
• Diabetic Macular Edema by Stage and Molecule Type
DelveInsight's Diabetic Macular Edema Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Diabetic Macular Edema product details are provided in the report. Download the Diabetic Macular Edema pipeline report to learn more about the emerging Diabetic Macular Edema therapies at:
https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Diabetic Macular Edema Therapeutics Market include:
Key companies developing therapies for Diabetic Macular Edema are Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotechnology, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Allegro Opthalmics, Bausch Health, Clearside Biomedical, KalVista Pharmaceuticals, and others.
Diabetic Macular Edema Pipeline Analysis:
The Diabetic Macular Edema pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Macular Edema with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Macular Edema Treatment.
• Diabetic Macular Edema key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Macular Edema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Macular Edema market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Macular Edema drugs and therapies-
https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Diabetic Macular Edema Pipeline Market Drivers
• Growing Prevalence of diabetes, development of novel therapies, investment in Research and Development activities are some of the important factors that are fueling the Diabetic Macular Edema Market.
Diabetic Macular Edema Pipeline Market Barriers
• However, high medical cost, lack of approved therapies and other factors are creating obstacles in the Diabetic Macular Edema Market growth.
Scope of Diabetic Macular Edema Pipeline Drug Insight
• Coverage: Global
• Key Diabetic Macular Edema Companies: Eluminex BioSciences, Ocugen, Innovent biologics, Curacle, GlaxoSmithKline, Exonate Limited, Ocuphire Pharma, Unity Biotechnology, Allgenesis Biotherapeutics Inc., Mylan, Kodiak Sciences, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Oxurion, Novartis, YD Life Science, Allegro, Opthalmics/Bausch Health, Clearside Biomedical, KalVista Pharmaceuticals, and others
• Key Diabetic Macular Edema Therapies: EB-102, OCU200, IBI324, CU06-1004, GSK-2798745, EXN407, APX3330, UBX1325, AG-73305, MYL-1701P, KSI-301, BEOVU (RTH258; brolucizumab), VABYSMO (faricimab), KSI-301, ADVM-022, GB-102, THR-149, LKA651, YD-312, Luminate (ALG-1001, Risuteganib), Xipere (CLS-TA), KVD001, and others
• Diabetic Macular Edema Therapeutic Assessment: Diabetic Macular Edema current marketed and Diabetic Macular Edema emerging therapies
• Diabetic Macular Edema Market Dynamics: Diabetic Macular Edema market drivers and Diabetic Macular Edema market barriers
Request for Sample PDF Report for Diabetic Macular Edema Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Diabetic Macular Edema Report Introduction
2. Diabetic Macular Edema Executive Summary
3. Diabetic Macular Edema Overview
4. Diabetic Macular Edema- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Macular Edema Pipeline Therapeutics
6. Diabetic Macular Edema Late Stage Products (Phase II/III)
7. Diabetic Macular Edema Mid Stage Products (Phase II)
8. Diabetic Macular Edema Early Stage Products (Phase I)
9. Diabetic Macular Edema Preclinical Stage Products
10. Diabetic Macular Edema Therapeutics Assessment
11. Diabetic Macular Edema Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Macular Edema Key Companies
14. Diabetic Macular Edema Key Products
15. Diabetic Macular Edema Unmet Needs
16 . Diabetic Macular Edema Market Drivers and Barriers
17. Diabetic Macular Edema Future Perspectives and Conclusion
18. Diabetic Macular Edema Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Macular Edema Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approval, NDA Approval, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 4006864 • Views: …
More Releases from DelveInsight Business Research

Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…

Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…

Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…

Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Update …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Macular
2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Co …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compound…
Macular Edema and Macular Degeneration Market Poised for 7.1% Growth, Set to Hit …
How Are the key drivers contributing to the expansion of the macular edema and macular degeneration market?
The growth of the macular edema and macular degeneration market is predicted to be driven by the escalating number of individuals suffering from diabetes. Diabetes is a long-term health condition that results in elevated levels of glucose in the bloodstream. The condition harms the eye's blood vessels, potentially leading to macular edema and macular…
Macular Edema and Macular Degeneration Market Outlook 2025-2034: Key Trends, Gro …
"How Big Is the Macular Edema and Macular Degeneration Market Expected to Be, and What Will Its Growth Rate Be?
The macular edema and macular degeneration market has seen significant growth in recent years. It will expand from $9.65 billion in 2024 to $10.43 billion in 2025, with a CAGR of 8.1%. Factors contributing to this growth include the aging population, increasing diabetes prevalence, early diagnosis and awareness, global initiatives in…
Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034
The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies.
Download White Paper: https://www.towardshealthcare.com/download-statistics/5375
Market Overview and Key Drivers
The macular…
Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024 …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $12.84…
Macular Edema and Macular Degeneration Market: Key Trends, Competitor Analysis, …
"Exploring the Global Macular Edema and Macular Degeneration Market: A Comprehensive Overview
Insights into Macular Edema and Macular Degeneration Market: Global Trends and Analysis
Macular Edema and Macular Degeneration Industry - Key Market Dynamics and Trends
The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The…